Results 51 to 60 of about 22,026 (263)

Clinical Practice Guideline for Evaluation and Management of Peripheral Nervous System Manifestations in Sjögren's Disease

Arthritis Care &Research, EarlyView.
Objective Sjögren's disease is an autoimmune disorder that can impact multiple organ systems, including the peripheral nervous system (PNS). PNS manifestations, which can exist concurrently, include mononeuropathies, polyneuropathies, and autonomic nervous system neuropathies.
Anahita Deboo, Robert Fox, Katherine M. Hammitt, Julie Frantsve‐Hawley, Matthew C. Baker, Stamatina Danielides, Eduardo De Sousa, Brent P. Goodman, Jennifer K. King, Steven Mandel, Ghaith Noaiseh, Pantelis P. Pavlakis, George Sarka, R. Hal Scofield, Arun Varadhachary, Daniel J. Wallace, Matt Makara, Nancy Carteron, Steven Carsons, in collaboration with the Consensus Expert Panel (CEP) members, G. Alden Adkins, Brittany Adler, Hossein Ansari, Senada Arabelovic, Alan Baer, Denis Balaban, Shamik Bhattacharyya, Evelyn Bromet, Krishna Chaganti, Kamal Chemali, Melissa Cortez, Schartess Culpepper, Paul Dellaripa, Dana Direnzo, Daniel El Bogdadi, Robert Fearon, Mehrnez Fischbach, Judi Furlong, Christopher Gibbons, Rachael Gordon, Thomas Grader Beck, Syed Haider, Larry Hollenbeck, Chadwick R. Johr, Stuart S. Kassan, Brian King, Octavia Kincaid, Eugene Kissin, Vasileios Kyttaris, Lindsay Lally, Brandon M. Law, Janet Lewis, Scott M. Lieberman, Amanda Lusa, Joseph Lutt, Rashmi Maganti, Arthur M. Mandelin, Sara McCoy, Kerry Neall, Timothy Niewold, Anne Louise Oaklander, Ruben A. Peredo‐Wende, Lynn Petruzzi, Mark A. Porter, Guada Respicio Duque, Tania Reyna, Nathaniel M. Robbins, Elliot D. Rosenstein, Laura Rosow, Breanna Ruthrauff, Amit Sachdev, Nora Sandorfi, Sarah Schafer, Elena Schiopu, Chokkalingam Siva, Daniel Small, Sara M. Stern, Lauren Stiles, Susan Stoddard, Jinny Tavee, Donald Thomas, Edward L. Treadwell, Nagagopal Venna, Steven Vernino, Frederick B. Vivino, Brittany Weber, Sepideh Yadollahi, Huiying Yu, Scott Zashin   +88 more
wiley   +1 more source

The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review

Diabetology & Metabolic Syndrome
Background Dipeptidyl peptidase 4 (DPP-4) plays a crucial role in breaking down various substrates. It also has effects on the insulin signaling pathway, contributing to insulin resistance, and involvement in inflammatory processes like obesity and type ...
L. M. Pechmann, F. I. Pinheiro, V. F. C. Andrade, C. A. Moreira   +3 more
doaj   +1 more source

Identification of phytoconstituents from Houttuynia cordata Thunb. as dipeptidyl peptidase-IV and sodium glucose cotransporter 2 inhibitors guided by molecular docking

Phytomedicine Plus
Purpose: Houttuynia cordata Thunb. is an edible medicinal herb belonging to the Saururaceae family. Although the effects of the plant extracts on several diabetic-related parameters have been documented in the past, there is no documentation of the ...
Careen Liza Pakyntein, Daiahun Thabah, Anita Kumari Rai, Donkupar Syiem   +3 more
doaj   +1 more source

Two-Year Therapeutic Efficacy and Safety of Initial Triple Combination of Metformin, Sitagliptin, and Empagliflozin in Drug-Naïve Type 2 Diabetes Mellitus Patients [PDF]

Diabetes & Metabolism Journal
Background We investigated the long-term efficacy and safety of initial triple therapy using metformin, a dipeptidyl peptidase-4 inhibitor, and a sodium-glucose cotransporter-2 inhibitor, in patients with type 2 diabetes mellitus. Methods We enrolled 170
Young-Hwan Park, Minji Sohn, So Yeon Lee, Soo Lim   +3 more
doaj   +1 more source

Identification and Characterization of Dipeptidyl Peptidase-IV Inhibitory Peptides from Oat Proteins

Foods, 2022
In this study, flavourzyme, papain, neutrase, and alcalase, as well as gastrointestinal digestion simulated with pepsin and pancreatin, were used to hydrolyze oat protein, and the dipeptidyl peptidase-IV (DPP-IV) inhibitory activities of the oat protein ...
Wei Wang, Xiaoqing Liu, Yiju Li, Haixi You, Zhipeng Yu, Liying Wang, Xuebo Liu, Long Ding   +7 more
doaj   +1 more source

Synthesis of new DPP-4 inhibitors based on a novel tricyclic scaffold [PDF]

, 2015
A novel molecular scaffold has been synthesized and its synthesis and incorporation into new analogues of biologically active molecules will be discussed.
Biftu T., Borne R. F., Chutian S., Drucker D. J., Drucker D. J., Hawkins P. C. D., Herman G. A., Juillerat-Jeanneret L., Kim D., Nauck M., Occhiato E. G., Orsakov C., Schwehm C., Thomsen I., Thornberry N. A.   +14 more
core   +3 more sources

Fibroblast Activation Protein Promotes Thoracic Aortic Dissection via PLAUR/ITGB1‐Mediated Pro‐inflammatory Macrophage Polarization

Advanced Science, EarlyView.
This study reveals that FAP promotes thoracic aortic dissection (TAD) through a nonenzymatic mechanism involving fibroblast‐macrophage crosstalk via the FAP/PLAUR/ITGB1/FAK axis. Targeting this pathway might offer a promising therapeutic strategy for TAD.
Hongqiao Zhu, Jianlie Wu, Ziyi Xu, Yifei Pei, Zaiping Jing, Jian Zhou, Rui Feng, Junjun Liu   +7 more
wiley   +1 more source

Acute Kidney Injury Associated with Linagliptin

Case Reports in Endocrinology, 2016
Linagliptin is a dipeptidyl peptidase-IV (DPP-IV) inhibitor that is approved for the treatment of type 2 diabetes mellitus. About 5% of linagliptin is eliminated by the kidneys and no dose adjustment is recommended in kidney impairment. We report a first
Deepak K. Nandikanti, Elvira O. Gosmanova, Aidar R. Gosmanov   +2 more
doaj   +1 more source

Dipeptidyl peptidase-4 activity is associated with urine albumin excretion in type 1 diabetes [PDF]

, 2017
AIMS: The inability of kidneys to prevent urinary protein leakage represents the earliest sign of renal damage in diabetic kidney disease (DKD). Recent data suggest the possible nephroprotective role of the dipeptidyl peptidase-4 (DPP-4) inhibitors ...
Blaslov, Kristina, Duvnjak, Lea, Nikolac Perković, Matea   +2 more
core   +1 more source

Dipeptidyl peptidase IV inhibitors as novel regulators of vascular disease [PDF]

Vascular Pharmacology, 2017
Dipeptidyl peptidase IV (DPP-IV) has been revealed as an adipokine with potential relevance in cardiovascular disease (CVD), while clinically used DPP-IV inhibitors have demonstrated beneficial cardiovascular effects in several experimental studies. Perivascular adipose tissue (PVAT) is a unique adipose tissue depot in close anatomical proximity and ...
Akoumianakis, I, Antoniades, C
openaire   +3 more sources